Ennaid Therapeutics | LSU grad has patent pending for drug to treat COVID-19
19718
post-template-default,single,single-post,postid-19718,single-format-standard,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-6.4.2,vc_non_responsive

LSU grad has patent pending for drug to treat COVID-19

20 Nov LSU grad has patent pending for drug to treat COVID-19

ATLANTA- An LSU graduate and Baton Rouge native who now lives in Georgia said her company has a patent pending on a drug that has shown promising results treating COVID-19 in lab tests.

Darnisha Harrison said as the country and Louisiana face another spike in cases, time was of the essence to let people know.

“Drosperinone has shown quite consistent efficacy in COVID-19 as a potential therapeutic,” Harrison said. “Dually targeted in blocking entry of COVID-19 at a rate of 70 percent and blocking replication at a rate of 80 percent.”

Harrison said her company, Ennaid Therapeutics is sharing the information because they have a moral and ethical responsibility.

“It’s a significant step in the direction of bringing this global crisis to an end and keeping the world safe,” Harrison said.

Continue reading HERE

No Comments

Post A Comment